[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fractures-hip\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fractures-hip":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,57,87],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":33,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100602937","phase-4-preoperative-use-of-peripheral-nerve-blocks-in-elderly-patients-with-hip-fractures-100602937",false,"NCT07130006","Preoperative Use of Peripheral Nerve Blocks in Elderly Patients With Hip Fractures","Preoperative Use of Peripheral Nerve Blocks in Elderly Patients With Hip Fractures: a Factorial Randomized Clinical Trial","Inclusion Criteria:\n\n* both sexes\n* 60 years old and older\n* diagnosed with a hip fracture resulting from low-energy trauma\n* scheduled surgery.\n\nExclusion Criteria:\n\n* polytraumatized patients\n* dementia and acute psychosis patients\n* patients for whom spinal anesthesia is contraindicated\n* patients with severe renal failure\n* patients for whom intravenous administration of tranexamic acid is contraindicated\n* patients with proven allergy and contraindications to dexamethasone, non-steroidal anti-rheumatic drugs, opioid analgesics, magnesium sulfate.","ALL","60 Years",{"count":19,"type":20},256,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","The goal of this clinical trial is to explore the effects of different peripheral nerve blocks in older adults with hip fractures. It will also explore the safety of preoperative administration of peripheral nerve blocks. The main questions this trial aims to answer are:\n\n* which peripheral nerve block is the best regarding analgesia\n* which peripheral nerve block eases positioning and decrease time necessary for applying spinal anesthesia?\n* which peripheral nerve block is associated with reduced intake of analgesics, both oral and intravenous?\n* which peripheral nerve block lasts long enough but does not interfere with the start of physical therapy?\n* what medical problems do respondents have during their hospitalization, after administration of peripheral nerve blocks, spinal anesthesia and surgery?\n* what medical problems arise as a consequence of their complex medical history? Researchers will compare respondents who receive peripheral nerve blocks to those who do not. Those who do not receive blocks will be given fentanyl preoperatively, which was until recently standard at our institution.\n\nAll respondents will, in addition to obligatory intraoperative monitoring,:\n\n* be thoroughly examined by anesthesiologists before surgery\n* be closely monitored after surgery, until their hospital discharge.",[26,27,28,29,30,31,32],"Fractures, Hip","Femoral Neck Fractures","Intertrochanteric Fractures","Subtrochanteric Fractures","Aged","Frail Older Adults","Elderly",[34,35,36,37,38,39,40,41,42,43],"elderly","ultrasound-guided","peripheral nerve blocks","intravenous fentanyl","spinal anaesthesia","EQ-5D-5L","visual analog scale","pain at rest","dynamic pain","hip fracture surgery","NOT_YET_RECRUITING","2025-08-11",{"date":47,"type":48},"2025-08-19","ACTUAL",{"date":50,"type":20},"2025-08-30",{"date":52,"type":20},"2026-03-31",{"name":54,"class":55},"University Hospital of Split","OTHER",1,{"id":58,"slug":4,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":63,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":64,"targetDuration":4,"studyType":21,"phases":66,"briefSummary":68,"conditions":69,"keywords":72,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":56},"100435247","NCT04947722","The PREVENT Trial: a Pragmatic Cluster Randomized Controlled Trial of a Multifaceted Fracture Prevention Model for Long-term Care","PREVENT","Inclusion Criteria:\n\n* Both profit and non-profit long-term care homes in Ontario, Canada.\n* Homes must have a minimum of 50 occupied beds to participate; there is no maximum home size for participation.\n* For both control and intervention homes, resident eligibility (and study cohorts) will be determined via the RAI-MDS 2.0 database.\n\nExclusion Criteria:\n\n* Residents identified as having end-stage disease, who are comatose, receiving hospice or respite care and who have an expected short stay (90 days or less).",true,{"count":65,"type":20},3060,[67],"NA","Hip fractures occur nearly twice as often for older adults residing in long-term care as they do in older adults of a similar age still living in other settings. Hip fractures are the leading cause of hospitalization and often result in loss of independence, problems with walking and sometimes death. To address this problem the PREVENT (Person-centered Routine Fracture PrEVENTion in LTC) program was designed for use in long-term care homes. PREVENT uses a tool (\"fracture risk calculator\") based on a residents electronic health record to capture who is most at risk of fracture due to osteoporosis and falls. The program then trains the health care team including doctors, pharmacists and nurses on the latest recommendations on how to best assist residents and their families in making treatment decisions. The healthcare teams are also given tools that help them stay on track such as templates for ordering medications, strategies to reduce falls and fractures and making care plans. The study will examine if this program is effective for decreasing hip fractures by assigning some homes to receive the PREVENT program (intervention group) and some homes to usual care (control group) and comparing the results.",[70,26,71],"Fracture","Osteoporosis",[73,74,75,76],"Long-Term Care","Fracture Risk","Falls","Knowledge Translation","RECRUITING","2025-06-27",{"date":80,"type":48},"2025-07-01",{"date":82,"type":48},"2024-06-19",{"date":84,"type":20},"2027-03-31",{"name":86,"class":55},"McMaster University",{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":63,"sex":16,"minAge":94,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":21,"phases":97,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":117},"100420387","g7-acetabular-system-with-vivacit-e-or-longevity-liner-pmcf-study-100420387","NCT04754087","G7 Acetabular System With Vivacit-E or Longevity Liner PMCF Study","Global, Multicenter, and Prospective Post-Market Clinical Follow-Up Study of the G7 Acetabular System With Vivacit-E and Longevity Highly Crosslinked Polyethylene (HXLPE) Liners & Instrumentation","Inclusion Criteria:\n\n* Patient must be a legal adult who has reached full skeletal maturity.\n* Patient must be treated for one of the following indications:\n* Noninflammatory degenerative joint disease including osteoarthritis and avascular necrosis\n* Rheumatoid arthritis\n* Correction of functional deformity\n* Treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement, unmanageable by other techniques\n* Revision procedures where other treatment or devices have failed\n* Patient must be able and willing to complete the protocol required follow-up visits.\n* Patient must be able and willing to sign the Institutional Review Board or Ethics Committee (IRB\u002FEC) approved informed consent.\n\nExclusion Criteria:\n\n* Patient presents with osteoporosis, which in the opinion of the Principal Investigator, may limit the subject's ability to support total hip arthroplasty using the study device.\n* Patient has a metabolic disorder that may impair bone formation.\n* Patient has osteomalacia.\n* Patient has distant foci of infections which may spread to the implant site or patient with infection, sepsis or osteomyelitis.\n* Patient has rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram.\n* Patient has a vascular insufficiency, muscular atrophy, or neuromuscular disease\n* Patient is a prisoner.\n* Patient is a current alcohol or drug abuser.\n* Uncooperative patient or patient with neurologic disorders who is incapable or unwilling to follow directions.\n* Patient is pregnant.","18 Years",{"count":96,"type":20},300,[67],"The main objectives of this study are to confirm the long-term safety, performance, and clinical benefits of the G7 Acetabular Shells when used with the Vivacit-E and Longevity HXLPE liners and instrumentation in primary and revision total hip arthroplasty.",[100,101,102,103,104,105,26,106],"Total Hip Arthroplasty","Degenerative Joint Disease of Hip","Avascular Necrosis of Hip","Rheumatoid Arthritis of Hip","Osteoarthritis, Hip","Osteoarthritis of Hip","Fracture of Hip","2025-06-13",{"date":109,"type":48},"2025-06-18",{"date":111,"type":48},"2021-07-07",{"date":113,"type":20},"2033-12-31",{"name":115,"class":116},"Zimmer Biomet","INDUSTRY",11]